Dyslipidemia: current approaches to pharmacological and non-pharmacological management

Read full text
Authors: I. A. Galochkin, Yu. S. Bakhareva
Cited by: 0
References: 81

Abstract

Relevance . The problem of dyslipidemia remains one of the most important in many countries, including the Russian Federation. The proportion of patients with familial hypercholesterolemia who have reached the target LDL level does not exceed 2 %; the target levels of lipid profile indicators in primary and secondary prevention of cardiovascular diseases are achieved in only 26 % of cases, which is associated with the prescription of incorrect statin doses; the absence of combination therapy with ezetimibe; extremely rare prescription of PCSK9 inhibitors and/or bempedoic acid due to lack of proper experience with their use and the novelty of these drugs; and insufficient awareness among doctors and patients about the need to achieve the target LDL level [1]. A systematic search of publications was conducted in the PubMed, Scopus, Web of Science, and eLibrary databases for the period 2018–2025. The following keywords were used: low-density lipoproteins, bempedoic acid, lipid profile target values. More than 100 sources meeting the inclusion criteria were selected and analyzed. Objective of the review: to systematize and critically analyze current approaches to non-pharmacological and pharmacological management of dyslipidemias with a focus on personalized therapeutic strategies and the integration of modern approaches into clinical practice. Results . The review discusses current pharmacological and non-pharmacological methods for treating dyslipidemia, such as treatment with statins, fibrates, PCSK9 inhibitors, and changes in dietary habits. Particular attention is given to the role of bempedoic acid due to the limited experience with its use in combined lipid disorder management. Conclusions . The implementation of combination therapy for the correction of dyslipidemia is a promising approach to improving treatment effectiveness and patient outcomes. Further integration of non-drug interventions into clinical practice and addressing the accessibility of new treatment methods are necessary.

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Lipid metabolism and disorders Cholesterol and Lipid Metabolism

Publication details

Journal / source
Ateroscleroz
Volume
21
Issue
4
Pages
440–452
Publication date
24 January 2026